Psilocybin for Veterans in 2026: What the Executive Order Actually Changed
In April 2026, President Trump signed an executive order directing federal agencies to expedite research into psychedelic treatments for veterans with PTSD and traumatic brain injury. The order was widely reported; what it actually does and doesn't do is less clear.
What the Order Does
Accelerated FDA review: The order directs the FDA to expedite Breakthrough Therapy review for psilocybin and MDMA applications specifically related to veterans' mental health. This doesn't change safety standards — it shortens the administrative timeline.
VA funding: The order allocates $50 million from the VA research budget for psychedelic mental health research over the following two years, distributed through competitive grant applications.
Research site expansion: The VA is directed to expand the number of approved research sites conducting psychedelic trials from 3 to 10, with a geographic distribution requirement.
Interagency coordination: Creates an interagency working group on veteran psychedelic therapy to reduce regulatory siloing between VA, FDA, DEA, and DoD.
What the Order Does NOT Do
It does not reschedule psilocybin or MDMA: Both remain Schedule I controlled substances. Veterans cannot legally access psilocybin therapy outside of approved clinical trials or state-legal programs.
It does not authorize VA providers to administer psychedelics: VA clinicians cannot currently administer psilocybin even in states where it is legal, pending federal law changes.
It does not create immediate access: The practical effect of the order will be felt 18–36 months from now as new trials open, not immediately.
Where Veterans Can Access Psilocybin Now
Oregon: Licensed service centers accept out-of-state visitors. Several centers have veteran-specific programs with facilitators who have military backgrounds. The Heroic Hearts Project has relationships with Oregon service centers and can facilitate referrals.
Colorado: Legal for adults 21+; healing centers are becoming operational in 2025–2026.
Clinical trials: VA and academic trials are actively recruiting. ClinicalTrials.gov lists open studies under "psilocybin PTSD veterans."
International: Several Jamaica-based retreats have veteran-specific programs operated outside US legal jurisdiction.
Organizations Supporting Veterans
- Heroic Hearts Project: Peer-support and referral network for veterans seeking psychedelic therapy
- Veterans Exploring Treatment Solutions (VETS): Connects veterans with clinical trials and legal access programs
- MAPS Veteran Research Program: Specifically studying MDMA-assisted therapy for veteran PTSD